February 2021

HEOR | Urothelial Carcinoma | Abstract 414

Treatment patterns among patients with advanced urothelial carcinoma following discontinuation of PD1/L1 inhibitor therapy

Tucatinib | Gastric or GEJ Cancers | TPS252

MOUNTAINEER-02 TIP: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma: Trial in Progress

Ladiratuzumab vedotin | Prostate Cancer | Abstract TPS185

SGNLVA-005 TIP: Open-Label, Phase 2 Study of Ladiratuzumab Vedotin (LV) for Advanced Gastric and Gastroesophageal Junction Adenocarcinoma (SGNLVA-005, Trial in Progress)

Enfortumab vedotin | Urothelial Carcinoma| Abstract 393

Primary results of EV-301: A phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial carcinoma

EV-201 Cohort 2: Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors